Current data on GLP-1 medication use, market growth, costs, side effects, and treatment access, with a focus on women considering physician-guided weight management.
The GLP-1 weight loss medication market has entered a period of rapid expansion, with the global market projected to reach $65.2 billion by 2033. For women seeking physician-guided treatment, particularly those in their 40s to 60s managing weight during perimenopause or menopause, understanding the current landscape of GLP-1 medications has become essential. These statistics reveal not just market momentum, but the real-world barriers patients face with affordability, access, and finding transparent care options.
Key Takeaways
- Market expansion continues: The GLP-1 agonists weight loss drugs market is growing at 13.1% CAGR from 2026 through 2033, with projections reaching $65.2 billion globally.
- Women lead adoption: 20% of women ages 50–64 have used GLP-1 agonists, the highest rate among demographic groups surveyed by RAND in 2025.
- Affordability remains critical: 56% of GLP-1 users report difficulty affording these medications, with 14% of ever-users stopping treatment due to cost.
- Telehealth access growing: 17% of people who have used GLP-1 drugs report obtaining them through online providers or websites.
- Compounded medications remain part of usage: 18% of current users reported taking compounded GLP-1 medications in Gallup's 2026 survey.
- Women-centered GLP-1 care: Majesta Health offers physician-guided weight management with transparent pricing and ongoing support through its planned programs.
Understanding the GLP-1 Market Landscape
The numbers behind GLP-1 adoption reveal a treatment category that has moved from specialized diabetes care into mainstream weight management. For anyone considering these medications, understanding market dynamics helps contextualize what options exist and why pricing varies so dramatically.
1. Global market valued at $20.9 billion in 2025
The GLP-1 agonists weight loss drugs market reached $20.9 billion in 2025, establishing it as a rapidly growing pharmaceutical category globally.
This estimate covers medications marketed specifically for weight loss, rather than every GLP-1 medication prescribed for diabetes.
Grand View Research also estimated the market would reach $27.5 billion in 2026, reflecting continued expansion.
2. Market projected to reach $65.2 billion by 2033
Industry analysts project the market will grow to $65.2 billion by 2033, representing more than triple its 2025 valuation.
The projection concerns global revenue from GLP-1 agonist weight loss drugs across the forecast period.
It is a market forecast, not a confirmed future result or an estimate of individual treatment outcomes.
3. 13.1% compound annual growth rate through 2033
The GLP-1 weight loss market is expanding at a projected 13.1% CAGR from 2026 to 2033.
This compound annual growth rate describes expected market revenue growth rather than growth in the number of patients.
The forecast covers seven years and depends on assumptions about medication availability, demand, and market conditions.
4. North America holds 77.2% market share
North America dominated the GLP-1 agonists weight loss drugs market with 77.2% revenue share in 2025, reflecting the region's substantial market presence.
This measurement concerns pharmaceutical revenue, not the proportion of North American adults using GLP-1 medications.
The United States accounted for the largest national market share within the report's regional analysis.
5. Semaglutide holds 60.5% market share
The semaglutide segment held 60.5% of the market for GLP-1 agonist weight loss drugs in 2025, according to Grand View Research.
This percentage measures the segment's share of market revenue rather than the proportion of prescriptions issued.
The report identifies semaglutide as the largest drug segment, while tirzepatide represents another major treatment category.
| Market indicator | Reported figure | Period |
|---|---|---|
| Global market value | $20.9 billion | 2025 |
| Estimated market value | $27.5 billion | 2026 |
| Projected market value | $65.2 billion | 2033 |
| Projected annual growth | 13.1% | 2026–2033 |
Source: Grand View Research, GLP-1 agonists weight loss drugs market report.
Current GLP-1 Usage and Adoption Statistics
Understanding who currently uses these medications, and how they access them, provides critical context for anyone evaluating their options. The data shows growth in adoption, with telehealth emerging as a significant access point.
6. 12% of U.S. adults reported taking GLP-1 medications in 2025
12% of U.S. adults reported currently taking a GLP-1 drug for weight loss, diabetes, or another chronic condition in KFF's November 2025 poll.
This represents approximately one in eight adults, across medical indications rather than weight loss alone.
The survey included 1,350 U.S. adults and was conducted between October 27 and November 2, 2025.
7. 11% use GLP-1s specifically for weight loss
The percentage of U.S. adults taking GLP-1 medications specifically for weight loss reached 11% in 2026, up from 3% in 2024.
Gallup collected the 2026 survey responses between May 28 and June 5, 2026.
The findings distinguish current weight-loss medication use from lifetime use and treatment for other conditions.
8. 15% have used GLP-1s for weight loss at some point
Looking at ever-use rather than current use, 15% of U.S. adults reported having used GLP-1 drugs for weight loss purposes at some point in 2026.
That compares with 6% reporting lifetime weight-loss use in Gallup's 2024 survey.
These estimates include people who previously used the medications but were no longer taking them when surveyed.
9. 11.8% of adults reported ever using GLP-1 medications in 2025
RAND's American Life Panel found that 11.8% of U.S. adults reported having taken a GLP-1 agonist at least once in 2025.
The survey included medication use for weight loss, diabetes, heart disease, and other chronic conditions.
RAND surveyed 8,793 adults in April and May 2025, using a different sample and methodology from KFF.
10. GLP-1 spending increased over 500% from 2018–2023
Total U.S. spending on GLP-1 receptor agonists increased by more than 500% between 2018 and 2023, according to research published in 2025.
The study reported spending of $13.7 billion in 2018 and $71.7 billion in 2023.
These figures cover GLP-1 receptor agonist medications across indications, not spending on weight-loss prescriptions alone.
11. 90% of Americans were aware of GLP-1 medications in 2026
Public awareness of GLP-1 drugs reached 90% in 2026, up from 80% in 2024, according to Gallup.
The survey measured awareness of GLP-1 medications intended for weight-loss purposes among U.S. adults.
Awareness does not establish whether respondents understand medication eligibility, contraindications, or differences between approved and compounded products.
Women and GLP-1 Weight Loss: Demographics That Matter
The demographic patterns in GLP-1 adoption reveal why women-centered care models have become increasingly relevant. Women, particularly those in midlife, report substantial use of these medications.
12. Women are more likely than men to use GLP-1s
Women were more likely than men to currently take a GLP-1 medication, with 15% of women versus 9% of men reporting current use.
These results came from KFF's national survey conducted in late 2025.
The figures include use for chronic medical conditions as well as weight management.
13. 20% of women ages 50–64 have used GLP-1 agonists
Women ages 50–64 showed the highest adoption rate at 20% among the demographic groups surveyed by RAND in 2025.
The statistic measures whether respondents had ever used a GLP-1 agonist, rather than current treatment.
It includes medications taken for weight loss and chronic conditions, without identifying menopause as the reason for treatment.
14. Adults ages 50–64 reported GLP-1 use at 18.5%
Across genders, adults ages 50–64 reported ever-use of 18.5% in RAND's April–May 2025 survey, the highest rate across its age groups.
Use was lower among respondents ages 18–29, 30–49, and 65 or older.
The survey's age-group estimates describe medication experience and should not be interpreted as treatment recommendations.
15. 27% of women interested in taking GLP-1s versus 18% of men
Among those who had never used GLP-1 medications, 27% of women expressed interest in taking one for weight loss compared with 18% of men.
KFF collected these responses during its October–November 2025 polling period.
Interest in treatment does not establish whether someone meets medical eligibility requirements or would receive a prescription.
16. 33.3% of adults with diabetes ages 50–64 used GLP-1 injectables
Among adults with diagnosed diabetes ages 50–64, 33.3% used GLP-1 injectables in 2024 to lower blood sugar or manage weight.
The CDC estimate comes from the 2024 National Health Interview Survey, published in August 2025.
It measures injectable medication use among adults with diagnosed diabetes, not all adults in the same age group.
| Age group | Men | Women |
|---|---|---|
| 18–29 | 2.5% | 4.1% |
| 30–49 | 7.2% | 15.1% |
| 50–64 | 16.8% | 20.0% |
| 65+ | 13.5% | 12.8% |
Source: RAND American Life Panel, April–May 2025. Percentages represent adults reporting ever using GLP-1 agonists.
For women seeking physician-guided care during perimenopause or menopause, these statistics help explain the relevance of age-specific treatment discussions. Platforms like Majesta focus specifically on connecting women with licensed physicians who can evaluate hormonal and metabolic health concerns alongside medical history and treatment suitability.
GLP-1 Diabetes Treatment Statistics
While weight loss drives much of the market growth, GLP-1 medications originated as diabetes treatments. These statistics show substantial adoption among patients with diagnosed diabetes.
17. 26.5% of adults with diabetes used GLP-1 injectables in 2024
Among U.S. adults with diagnosed diabetes, 26.5% used GLP-1 injectables to lower blood sugar or lose weight in 2024.
The CDC estimated this represented approximately 6.9 million adults with diagnosed diabetes.
The findings concern injectable GLP-1 medication use at the time of interview, rather than lifetime exposure.
18. 155% increase in diabetes-related GLP-1 use from 2018–2022
The percentage of adults with type 2 diabetes using GLP-1 injectables increased 155%, from 7.6% in 2018 to 19.4% in 2022.
The CDC summarized findings from the Medical Expenditure Panel Survey in its August 2025 data brief.
The increase refers specifically to adults with type 2 diabetes, rather than the overall U.S. adult population.
19. Hispanic adults with diabetes show higher GLP-1 adoption
Hispanic adults with diagnosed diabetes were more likely to use GLP-1 injectables at 31.3% than non-Hispanic Asian adults at 12.1%.
The CDC also reported use among non-Hispanic Black adults at 26.5% and non-Hispanic White adults at 26.2%.
These estimates reflect 2024 survey data and describe differences in reported medication use across demographic groups.
Cost, Insurance, and Affordability Statistics
Affordability represents a significant barrier to GLP-1 treatment. These statistics reveal why transparent pricing, insurance coverage, and understanding total treatment costs have become important factors in patient decision-making.
20. 56% of GLP-1 users find medications difficult to afford
More than half of people who had used GLP-1 drugs, 56%, reported difficulty affording these medications in KFF's 2025 poll.
Among respondents with health insurance, 55% also described affordability difficulties.
The findings include patients who used GLP-1 medications for weight loss and other medical conditions.
21. 14% stopped taking GLP-1s due to cost
14% of adults who had used GLP-1s reported no longer taking them specifically because of cost concerns in 2025.
A similar share, 13%, said they had stopped because of side effects.
These responses identify reported reasons for stopping treatment, without establishing whether individuals later restarted medication.
22. 27% of insured patients paid the full cost themselves
Even among people with health insurance, 27% paid the full cost of GLP-1 drugs themselves, according to KFF's November 2025 findings.
The figure applies to insured adults who had used GLP-1 medications.
Having health insurance therefore did not necessarily mean respondents received financial assistance for their prescriptions.
Compounded GLP-1 Usage Statistics
Compounded medications are used by some patients seeking GLP-1 treatment. These statistics reflect reported usage patterns, though patients should understand the regulatory distinction.
Compounded medications are not FDA-approved as final products and are not generic versions of, equivalent to, or interchangeable with any FDA-approved medication.
23. 18% of GLP-1 users take compounded versions
18% of current GLP-1 users reported taking compounded or custom-mixed versions of these medications in Gallup's 2026 survey.
The survey distinguished compounded preparations from brand-name prescription medications.
Reported use does not establish that compounded products have undergone FDA review for safety, effectiveness, or quality.
24. 36% of compounded users switched from brand-name medications
Among those using compounded GLP-1 medications, 36% previously took brand-name medications before switching, according to Gallup's 2026 findings.
Cost or insurance coverage was the most commonly cited primary reason for switching among these respondents.
This statistic describes treatment history and does not establish clinical equivalence between different formulations.
25. 66% of GLP-1 users take brand-name medications
Brand-name GLP-1 medications comprised 66% of current usage in Gallup's 2026 findings, compared with 18% using compounded versions.
Another 13% of respondents were unsure whether they were using a brand-name medication.
These results reflect survey participants' reported medication types rather than independently verified pharmacy records.
Side Effects and Treatment Discontinuation
Understanding side effect profiles and discontinuation rates helps set realistic expectations for anyone considering GLP-1 treatment. Physician oversight is important for managing these challenges.
26. 52% of surveyed GLP-1 users experienced nausea
About 52% of surveyed GLP-1 users reported experiencing nausea, with 43.2% describing it as mild and 8.8% as serious.
RAND collected these responses from adults who reported having used GLP-1 agonists in 2025.
These self-reported rates are not interchangeable with adverse-event frequencies from clinical trials of specific medications.
27. 34.3% experienced diarrhea
Approximately 34.3% of surveyed users reported diarrhea as a side effect, with 26.8% describing it as mild and 7.5% as serious.
The findings were based on RAND's April–May 2025 American Life Panel survey.
The estimates cover multiple GLP-1 medications and are not specific safety rates for compounded preparations.
28. 19.8% experienced vomiting
19.8% of surveyed GLP-1 users reported vomiting, with 14.4% describing it as mild and 5.4% as serious.
RAND reported these findings in its August 2025 research report.
Persistent vomiting, dehydration, or severe gastrointestinal symptoms warrant medical assessment rather than independent medication adjustments.
29. 64.8% discontinued within one year without type 2 diabetes
Among individuals taking GLP-1 receptor agonists for overweight or obesity without type 2 diabetes, 64.8% discontinued within one year, compared with 46.5% of those with type 2 diabetes.
The 2025 JAMA Network Open study analyzed 125,474 adults starting eligible GLP-1 medications.
Researchers defined discontinuation as a gap of at least 60 days without medication available.
| Finding | Reported percentage | Research source |
|---|---|---|
| Nausea | 52.0% | RAND, 2025 |
| Diarrhea | 34.3% | RAND, 2025 |
| Vomiting | 19.8% | RAND, 2025 |
| One-year discontinuation without diabetes | 64.8% | JAMA, 2025 |
Sources: RAND and JAMA Network Open. RAND figures reflect self-reported side effects; the JAMA figure reflects a separate observational cohort.
These discontinuation rates highlight the importance of ongoing physician support. Majesta's planned injection plans include monthly physician check-ins and care-team messaging to help patients discuss side effects and treatment concerns with their clinicians.
Access and Treatment Pathways
How patients access GLP-1 treatment has evolved significantly, with telehealth playing an increasingly important role.
30. 17% obtained GLP-1s from online providers
17% of adults who had used GLP-1 drugs reported obtaining them through an online provider or website in KFF's 2025 poll.
Most respondents, 76%, reported obtaining GLP-1 drugs through one of their existing physicians.
These categories describe reported access pathways and do not establish whether prescriptions were issued during virtual or in-person visits.
For those interested in how telehealth weight management works, Majesta offers a structured pre-enrollment process: a 2-minute medical assessment, review by an independent physician licensed in the patient's state, and an individualized treatment plan if appropriate.
As of November 20, 2026, Majesta's early-access registration was available, but treatment enrollment had not been confirmed open. Completing the assessment does not guarantee approval or a prescription.
Future Projections: What 2027 and Beyond May Bring
The trajectory of GLP-1 adoption suggests continued growth, with several factors shaping the market through 2027 and beyond.
Key projections and trends include:
- The global GLP-1 agonist weight loss drugs market is projected to reach $65.2 billion by 2033.
- The market is forecast to grow at a 13.1% annual rate between 2026 and 2033.
- Employer coverage remains variable, with 33% of the largest firms covering GLP-1 medications primarily for weight loss in 2026.
- U.S. adult obesity prevalence was 36.4% in 2026, based on Gallup's self-reported height and weight data, compared with 39.9% in 2022. These observational figures do not establish that GLP-1 use caused the decline.
Make Informed GLP-1 Weight Management Decisions With Majesta
The latest GLP-1 statistics show growing medication use, persistent affordability concerns, and substantial differences in treatment access. For women navigating perimenopause, menopause, or other weight-management challenges, understanding these findings is an important starting point.
Majesta offers a women-centered approach to evaluating GLP-1 treatment through independent, U.S.-licensed physicians. Its care model emphasizes transparent pricing, individualized medical decisions, and ongoing support.
Majesta's planned injection options include:
- Essential: Compounded semaglutide/glycine/B12 injection, $159 for the first month, then $289/month.
- Performance: Compounded tirzepatide/glycine/B12 injection, $269 for the first month, then $399/month.
- Physician-guided care: Medical assessment, physician consultation, monthly check-ins, and care-team messaging.
- Transparent pricing: Physician care, prescribed medication, and shipping included in the applicable plan price.
These medications are compounded preparations, not FDA-approved final products. A licensed physician determines whether treatment is clinically appropriate.
Majesta's early-access assessment is available before treatment enrollment opens. There is no payment or medication order simply for joining early access, and nothing is charged unless a physician approves treatment.
Ready to explore your options? Start your assessment to begin the physician-review process when enrollment becomes available.
Before You Consider GLP-1 Treatment
Discuss your medical history, current medications, pregnancy plans, and possible contraindications with a licensed healthcare professional before considering GLP-1 medication. If you are pregnant, planning pregnancy, or using hormonal contraception, ask about medication-specific precautions.
FDA-approved semaglutide and tirzepatide products carry important warnings and contraindications. The prescribing clinician should review these with you, including a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.
Do not independently start, stop, or change medication without guidance from your prescribing clinician.
When to Get Help Right Away
Seek urgent medical attention for severe or persistent abdominal pain, especially when accompanied by vomiting. These symptoms may indicate pancreatitis or another serious medical problem requiring evaluation.
Call 911 for chest pain, difficulty breathing, fainting, or signs of a severe allergic reaction, such as swelling of the face, lips, tongue, or throat.
Contact your prescribing clinician promptly about persistent vomiting, dehydration, severe gastrointestinal symptoms, or other concerning treatment-related effects.
This article is for informational purposes only and does not constitute medical advice, diagnosis or treatment. It does not recommend starting, stopping or changing any medicine.
Sources checked November 20, 2026.
Frequently Asked Questions
What percentage of people lose weight on GLP-1 medications?
Individual results vary significantly based on baseline weight, treatment adherence, lifestyle modifications, and overall health. Clinical trials of specific FDA-approved medications have demonstrated weight reduction, but their results cannot be directly applied to compounded preparations. A licensed physician can evaluate your medical circumstances and explain realistic treatment expectations.
Why do so many people stop taking GLP-1 medications?
Research found that 64.8% of patients without type 2 diabetes discontinued treatment within one year. Major factors associated with stopping treatment include cost, adverse effects, and individual treatment circumstances. Physician oversight and regular check-ins can help patients address concerns and discuss appropriate treatment decisions.
Are compounded GLP-1 medications safe and effective?
Compounded medications are not FDA-approved as final products and are not generic versions of, equivalent to, or interchangeable with any FDA-approved medication. The FDA does not independently review compounded drugs for safety, effectiveness, or quality before marketing. Patients should discuss the FDA's compounding concerns with their prescribing clinician. Majesta works with Belmar Pharma Solutions and Strive Pharmacy and holds LegitScript Healthcare Merchant Certification.
Why are women more likely to use GLP-1 medications?
Women reported higher GLP-1 usage than men in KFF's 2025 survey, with 15% versus 9% reporting current use. RAND separately found that women ages 50–64 had the highest lifetime usage among its demographic groups. These findings do not establish why women use the medications more frequently. Hormonal changes during perimenopause and menopause can also affect body composition and weight management.
Can I get GLP-1 medications through telehealth?
Yes. 17% of previous GLP-1 users in KFF's 2025 poll reported obtaining medications through online providers or websites. Telehealth platforms can connect patients with licensed physicians who evaluate eligibility, prescribe when appropriate, and provide follow-up care. Completing an online assessment does not guarantee treatment approval.
Sources
- 1.GLP-1 Agonists Weight Loss Drugs Market Report · Grand View Research · accessed
- 2.KFF Health Tracking Poll: Prescription Drug Costs and GLP-1 Use · KFF · accessed
- 3.In U.S., GLP-1 Usage Reaches New High · Gallup · accessed
- 4.New Weight Loss Drugs: GLP-1 Agonist Use and Side Effects in the United States · RAND Corporation · accessed
- 5.GLP-1 Injectable Use Among Adults With Diagnosed Diabetes: United States, 2024 · CDC, National Center for Health Statistics · accessed
- 6.Spending on Glucagon-Like Peptide-1 Receptor Agonists Among US Adults · JAMA Network Open · accessed
- 7.Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity · JAMA Network Open · accessed
- 8.2026 Employer Health Benefits Survey · KFF · accessed
- 9.FDA's Concerns With Unapproved GLP-1 Drugs Used for Weight Loss · U.S. Food and Drug Administration · accessed
- 10.Compounding and the FDA: Questions and Answers · U.S. Food and Drug Administration · accessed
Is this available in your state?
Telehealth rules differ by state, and so does what a physician can prescribe remotely. Each state page covers the local telehealth requirements, whether a video visit is required, and the current status of our physician coverage there.
- California
- Texas
- Florida
- New York
- Pennsylvania
- Illinois
- Ohio
- Georgia
- North Carolina
- Michigan
- Arizona
- Washington
